TABLE 1.
Clinicopathological characteristics of LUSC patients in the TCGA cohort.
| LUSC | |||
|---|---|---|---|
| Number | Percentage | ||
| Total | 498 | 100 | |
| Age | 33–90 | ||
| ≤65 | 189 | 37.95% | |
| >65 | 303 | 60.84% | |
| unknown | 6 | 1.21% | |
| Gender | |||
| Female | 130 | 26.10% | |
| Male | 368 | 73.90% | |
| Stage | |||
| Stage I | 243 | 48.80% | |
| Stage II | 160 | 32.13% | |
| Stage III | 84 | 16.87% | |
| Stage IV | 7 | 1.40% | |
| unknown | 4 | 0.80% | |
| Tumor (T) | |||
| T1 | 114 | 22.89% | |
| T2 | 290 | 58.23% | |
| T3 | 70 | 14.06% | |
| T4 | 24 | 4.82% | |
| Lymph Node (N) | |||
| N0 | 317 | 63.65% | |
| N1 | 130 | 26.10% | |
| N2 | 40 | 8.03% | |
| N3 | 5 | 1.01% | |
| NX | 6 | 1.21% | |
| Metastasis (M) | |||
| M0 | 410 | 82.33% | |
| M1 | 7 | 1.41% | |
| MX | 77 | 15.46% | |
| unknown | 4 | 0.80% | |
LUSC, lung squamous cell carcinoma.